- /
- Supported exchanges
- / US
- / KRRO.NASDAQ
Frequency Therapeutics Inc (KRRO NASDAQ) stock market data APIs
Frequency Therapeutics Inc Financial Data Overview
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. Its lead product candidate is KRRO-110 which is in Phase 1/2 clinical trial for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Frequency Therapeutics Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Frequency Therapeutics Inc data using free add-ons & libraries
Get Frequency Therapeutics Inc Fundamental Data
Frequency Therapeutics Inc Fundamental data includes:
- Net Revenue: 7 371 K
- EBITDA: -89 615 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-18
- EPS/Forecast: -2.6775
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Frequency Therapeutics Inc News
New
Korro Bio (KRRO): Assessing Valuation After Clinical Setbacks, Layoffs, and Strategic Pivot
Korro Bio (KRRO) stock saw heavy trading activity after the company announced its lead candidate KRRO-110 failed to reach key protein targets in a Phase 1/2a clinical trial. The disappointing data pro...
Dow’s big drop after a record close is fairly rare. How doubts about December rate cut are weighing on Wall Street.
Stocks were swept up in a broad-based selloff on Thursday. - AFP via Getty Images It was an unusually rough day on Wall Street. Major U.S. equity indexes, including the S&P 500 index, Nasdaq Composi...
Top Midday Decliners
Korro Bio's (KRRO) move to prioritize GaINac-conjugated programs that target the liver is the pragma PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Korro Bio stock fell after missing expectations in early stage KRRO-110 trial
[Colorful DNA helix] Stanislaw Pytel/DigitalVision via Getty Images Korro Bio (KRRO [https://seekingalpha.com/symbol/KRRO]) shares fell following results from its early-stage clinical trial of KRRO-1...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.